Correlation of Peripheral Chimeric Antigen Receptor T-cell (CAR-T Cell) mRNA Expression Levels with Toxicities and Outcomes in Patients with Diffuse Large B-cell Lymphoma

Autor:	Messerli C; University Hospital and University of Bern, Department of Medical Oncology, Bern, Switzerland, Wiedemann G; University Hospital and University of Bern, Department of Hematology and Central Hematology Laboratory, Bern, Switzerland, Porret N; University Hospital and University of Bern, Department of Hematology and Central Hematology Laboratory, Bern, Switzerland, Nagler M; University Institute of Clinical Chemistry, University Hospital and University of Bern, Bern, Switzerland, Seipel K; University of Bern, Department for Biomedical Research, Bern, Switzerland, Jeker B; University Hospital and University of Bern, Department of Medical Oncology, Bern, Switzerland, Novak U; University Hospital and University of Bern, Department of Medical Oncology, Bern, Switzerland, Zeerleder S; University Hospital and University of Bern, Department of Hematology and Central Hematology Laboratory, Bern, Switzerland, Bacher U; University Hospital and University of Bern, Department of Hematology and Central Hematology Laboratory, Bern, Switzerland, Pabst T; University Hospital and University of Bern, Department of Medical Oncology, Bern, Switzerland
Jazyk:	angličtina
Zdroj:	Turkish journal of haematology : official journal of Turkish Society of Haematology [Turk J Haematol] 2023 Aug 31; Vol. 40 (3), pp. 187-196. Date of Electronic Publication: 2023 Jul 31.
DOI:	10.4274/tjh.galenos.2023.2023.0136
Abstrakt:	Cytokine-release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) are significant complications in patients with relapsed/refractory diffuse large B-cell lymphoma undergoing chimeric antigen receptor T-cell (CAR-T cell) therapy. However, it remains unclear whether CAR-T cell expression itself is clinically relevant. We assessed CAR-T cell mRNA expression and DNA concentration by digital droplet PCR in peripheral blood from 14 sequential CAR-T cell recipients. Patients were grouped according to CAR-T cell peak expression. Patients with high CAR-T cell peak expression (8 patients; 57%) had higher rates of ICANS (p=0.0308) and intensive care unit admission (p=0.0404), longer durations of hospitalization (p=0.0077), and, although not statistically significant, a higher rate of CRS (p=0.0778). There was a correlation of CAR-T cell mRNA expression with DNA concentration, but CAR-T cell expression levels failed to correlate to response or survival. Our data suggest that higher CAR-T cell peak mRNA expression is associated with increased risk for ICANS and possibly CRS, requiring further investigation in larger studies. Competing Interests: Conflict of Interest: No conflict of interest was declared by the authors. (©Copyright 2023 by Turkish Society of Hematology Turkish Journal of Hematology, Published by Galenos Publishing House.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu Plný text ve formátu PDF